Amy Kosranabout 1 year ago
Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT
The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.
Source: https://www.medscape.com/viewarticle/998373?src=mbl_msp_android&ref=shareOther commentsSign in to post comments. You don't have an account? Sign up now!
Related posts
Nongingival Cyclosporine HyperplasiaNongingival Cyclosporine Hyperplasia.Drug Trial PhasesAnti Cancer Drug classificationAllergic Mucosal Reaction to Systemic Drug Administration.Lichenoid Drug Reaction to Allopurinol.Allergic Mucosal Reaction to Systemic Drug Administration.Identify the DrugIdentify the DrugIdentify the Drug